Dong Sung Pharm. Shareholders Slam Administrator Who Caused Trading Suspension: "Ignoring Responsibility, Demanding Only Consent"
Brand Refactoring, the largest shareholder and a group of shareholders opposing the post-approval M&A, stated that shareholder backlash is growing as Dong Sung Pharm. is moving to collect shareholder consents through an agency. In particular, they are strongly raising issues with what they call "an act of demanding trust without presenting any responsible alternatives."
On the 5th, Brand Refactoring said, "Na Wonkyun, former CEO and current administrator of Dong Sung Pharm., applied for rehabilitation proceedings even though he could have prevented a default on debt amid the company’s liquidity crisis, and as a result Dong Sung Pharm. ended up in the critical situation of trading suspension," adding, "Shareholders see this process not as a simple management failure, but as a decision that can hardly avoid suspicions of being intentional."
The problem lies in what followed. Although the actual damage from the trading suspension was borne by existing shareholders, Dong Sung Pharm. under the administrator system has been criticized for merely repeating the abstract message that it is 'staking everything on the resumption of trading,' without presenting any concrete compensation plan or alternative scenario for these shareholders.
Among shareholders, there is also a cynical reaction that "what should really have been prevented was not the trading suspension, but a short-term default of only several hundred million won."
Brand Refactoring and the shareholders opposing the post-approval M&A particularly point out that the very structure of the post-approval M&A, which brought in a third party, has caused massive dilution and losses to existing shareholder value. In this process, shareholders were deprived of their right to choose and ultimately had to endure the worst-case scenario of trading suspension.
Nevertheless, as the same responsible party is again asking for shareholder consent, criticism is mounting that "before talking about trust, there must first be accountability and an explanation."
Shareholders are making roughly three demands: a clear explanation of the decision-making process that led to the trading suspension and of the administrator’s responsibility; the presentation of realistic alternatives, other than the post-approval M&A, that can minimize damage to existing shareholders; and a rehabilitation scenario that is not centered on a third party but can be accepted by both shareholders and creditors.
Brand Refactoring stated, "The original purpose of rehabilitation proceedings is not to serve as an exit strategy for particular individuals or groups, but to normalize the company and its stakeholders," and emphasized, "If one is a responsible management body, before asking for trust, one must first make clear why this situation occurred and how it will be rectified."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
They added, "Trading resumption is not achieved by slogans. Shareholders have already waited long enough and suffered enough damage. What Dong Sung Pharm. needs now is not words asking to 'trust us,' but options that embody accountability and alternatives. Otherwise, this attempt to obtain shareholder consent is highly likely to go down as yet another breach of trust."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.